HER-2/neu Testing in Breast Carcinoma: A Combined Immunohistochemical and Fluorescence In Situ Hybridization Approach

Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.

Mark D. Pegram, A. Lipton, Daniel F. Hayes et al. · Journal of Clinical Oncology · 1998 · 1.1K citations

Medicine, Oncology, Pharmacology +17

c-erbB-2 Expression and Response to Adjuvant Therapy in Women with Node-Positive Early Breast Cancer

Hyman B. Muss, Ann D. Thor, Donald A. Berry et al. · New England Journal of Medicine · 1994 · 968 citations · Full text

Medicine, Oncology, Breast Oncology +15

Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.

B.A. Gusterson, RD Gelber, Aron Goldhirsch et al. · Journal of Clinical Oncology · 1992 · 843 citations

Medicine, Oncology, Breast Oncology +13

HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas.

Michael F. Press, Leslie Bernstein, P. Thomas et al. · Journal of Clinical Oncology · 1997 · 810 citations

Medicine, Molecular Biology, Oncology +14

erbB-2, p53, and Efficacy of Adjuvant Therapy in Lymph Node-Positive Breast Cancer

Ann D. Thor, Donald A. Berry, Daniel R. Budman et al. · JNCI Journal of the National Cancer Institute · 1998 · 618 citations · Full text

Medicine, Oncology, Pharmacology +16